| __timestamp | Ligand Pharmaceuticals Incorporated | PTC Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22570000 | 44820000 |
| Thursday, January 1, 2015 | 24378000 | 82080000 |
| Friday, January 1, 2016 | 26621000 | 97130000 |
| Sunday, January 1, 2017 | 28653000 | 121271000 |
| Monday, January 1, 2018 | 37734000 | 153548000 |
| Tuesday, January 1, 2019 | 41884000 | 202541000 |
| Wednesday, January 1, 2020 | 64435000 | 245164000 |
| Friday, January 1, 2021 | 57483000 | 285773000 |
| Saturday, January 1, 2022 | 70062000 | 325998000 |
| Sunday, January 1, 2023 | 52790000 | 332540000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. From 2014 to 2023, PTC Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated have shown contrasting approaches to SG&A cost management. PTC Therapeutics has seen a significant increase in SG&A expenses, rising from approximately $45 million in 2014 to over $332 million in 2023, marking a staggering 638% increase. In contrast, Ligand Pharmaceuticals has managed a more modest increase of 134% over the same period, from around $23 million to $53 million. This data suggests that Ligand Pharmaceuticals has been more effective in controlling its SG&A costs relative to its revenue growth. As investors and stakeholders evaluate these companies, understanding their cost management strategies could provide valuable insights into their operational efficiencies and long-term sustainability.
SG&A Efficiency Analysis: Comparing Zoetis Inc. and PTC Therapeutics, Inc.
Comparing SG&A Expenses: GSK plc vs Ligand Pharmaceuticals Incorporated Trends and Insights
Who Optimizes SG&A Costs Better? Alnylam Pharmaceuticals, Inc. or PTC Therapeutics, Inc.
Breaking Down SG&A Expenses: Viatris Inc. vs PTC Therapeutics, Inc.
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Ligand Pharmaceuticals Incorporated
Comparing SG&A Expenses: Blueprint Medicines Corporation vs Ligand Pharmaceuticals Incorporated Trends and Insights
Operational Costs Compared: SG&A Analysis of Lantheus Holdings, Inc. and Ligand Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of Axsome Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Comparing SG&A Expenses: PTC Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights
Operational Costs Compared: SG&A Analysis of Ligand Pharmaceuticals Incorporated and Mesoblast Limited
Breaking Down SG&A Expenses: Ligand Pharmaceuticals Incorporated vs Novavax, Inc.
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Xencor, Inc.